NASDAQ · IBRX
Healthcare · Biotechnology
$8.29
Down-$0.45 (-5.15%)
Updated Nov 1, 2026, 5:24 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · IBRX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
IBRX closed at $8.29 after 20 trading sessions, down 20.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $8.48 | $8.725 | $8.1223 | $8.29 | 8.96M |
| Oct 29, 2026 | $8.75 | $8.935 | $8.5601 | $8.74 | 7.15M |
| Oct 28, 2026 | $8.61 | $8.83 | $8.48 | $8.81 | 7.17M |
| Oct 27, 2026 | $7.82 | $8.685 | $7.765 | $8.63 | 10.51M |
| Oct 26, 2026 | $8.23 | $8.28 | $7.75 | $7.81 | 11.05M |
| Oct 23, 2026 | $8.21 | $8.355 | $8.05 | $8.22 | 5.94M |
| Oct 22, 2026 | $8.53 | $8.84 | $8.02 | $8.31 | 12.74M |
| Oct 21, 2026 | $8.79 | $8.99 | $8.32 | $8.64 | 11.51M |
| Oct 20, 2026 | $8.31 | $8.90 | $8.11 | $8.77 | 14.11M |
| Oct 19, 2026 | $9.19 | $9.6972 | $8.305 | $8.42 | 19.57M |
| Oct 16, 2026 | $10.02 | $10.02 | $9.02 | $9.18 | 21.51M |
| Oct 15, 2026 | $10.20 | $10.50 | $9.815 | $10.00 | 20.01M |
| Oct 14, 2026 | $9.69 | $10.455 | $9.35 | $9.91 | 30.23M |
| Oct 13, 2026 | $10.00 | $10.0599 | $9.56 | $9.80 | 11.62M |
| Oct 12, 2026 | $10.59 | $10.62 | $10.05 | $10.12 | 11.06M |
| Oct 9, 2026 | $9.95 | $10.80 | $9.87 | $10.51 | 18.66M |
| Oct 8, 2026 | $9.63 | $10.045 | $9.43 | $9.91 | 10.49M |
| Oct 7, 2026 | $9.50 | $9.93 | $9.33 | $9.75 | 11.78M |
| Oct 6, 2026 | $10.325 | $10.36 | $9.61 | $9.69 | 16.89M |
| Oct 5, 2026 | $10.76 | $10.81 | $10.125 | $10.38 | 16.87M |
The latest Smart Investors Daily articles mentioning IBRX.
Company
Market Activity
Research & News
IBRX research
Company profile and research snapshot.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 15, 2026 | Jefferies | Buy | — |
| Jun 2, 2026 | HC Wainwright & Co. | Buy | — |
| May 21, 2026 | BTIG | Buy | — |
| May 20, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 21, 2026
ImmunityBio is nearing final results from a trial testing whether adding ANKTIVA to BCG improves complete response rates and response durability in patients with BCG-naïve bladder cancer.
Yahoo · Oct 21, 2026
CULVER CITY, Calif., October 21, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), its randomized, controlled, registrational trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) versus BCG alone in patients with BCG-naïve NMIBC. The chemotherapy-free combination is delivered directly into the bladder.
Benzinga · Oct 21, 2026
Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle invasive bladder
Benzinga · Oct 21, 2026
Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle invasive bladder
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IBRX.
